Aducanumab: A Novel Drug for Alzheimer's Disease; Future Challenges in Treatment

	Aducanumab: A Novel Drug for Alzheimer's Disease; Future Challenges in Treatment
Advances in Pharmacology and Therapeutics Journal
Volume 2, Issue 1 - Serial Number 3, September 2022, Pages 1-3 PDF (226.23 K)
Document Type: Letter to editor
DOI: 10.18502/aptj.v2i1.10649
Authors
Reza Bidaki; Yekta Rameshi; Farahnaz Hoseinzade; Fatemeh Saghafi^*
Abstract
Dear Editor, Alzheimer's disease (AD) is a common frustrating disease among older adults. It imposes a high economic and medical burden on society and families. Although Alzheimer's disease is a progressively disabling psychiatric-neurological disorder, and there is no effective drug stopping or delaying the disease process over the last decade, lots of research has been done on some antibodies against amyloid plaques, which are the main etiology of this disease (1). By June 2021, Aducanumab (Aduhelm®) was approved by the Food and Drug Administration (FDA); it was demonstrated that this drug could be an effective intervention to prevent and remove the formation of amyloid plaques (2). Because of the lack of extensive research on this drug, many physicians and patients are concerned about its efficacy and side effects. However, many Alzheimer's specialists are satisfied with the approval of this drug.
Keywords
Alzheimer’s disease; Aducanumab; Amyloid-β

Statistics Article View: 136 PDF Download: 100